What is HC Wainwright’s Forecast for NRXP FY2025 Earnings?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Research analysts at HC Wainwright boosted their FY2025 EPS estimates for NRx Pharmaceuticals in a research note issued to investors on Thursday, March 20th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings of ($0.06) per share for the year, up from their prior estimate of ($0.07). HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10).

A number of other analysts have also recently weighed in on NRXP. D. Boral Capital reissued a “buy” rating and issued a $31.00 price target on shares of NRx Pharmaceuticals in a research report on Monday. Ascendiant Capital Markets upped their price target on NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, December 2nd.

NRx Pharmaceuticals Price Performance

NRXP opened at $2.07 on Monday. NRx Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $6.01. The company has a market capitalization of $35.02 million, a P/E ratio of -0.97 and a beta of 1.22. The firm’s fifty day moving average price is $2.77 and its two-hundred day moving average price is $2.04.

Hedge Funds Weigh In On NRx Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Anson Funds Management LP bought a new stake in NRx Pharmaceuticals during the 3rd quarter worth about $241,000. Millennium Management LLC acquired a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at approximately $61,000. Squarepoint Ops LLC bought a new position in NRx Pharmaceuticals in the 4th quarter worth approximately $56,000. AdvisorShares Investments LLC lifted its holdings in NRx Pharmaceuticals by 138.5% during the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after buying an additional 180,229 shares in the last quarter. Finally, Sassicaia Capital Advisers LLC bought a new position in NRx Pharmaceuticals in the 4th quarter valued at $33,000. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.